Core Insights - Smoore International reported its Q1-3 2025 financial data, with revenue of 10.21 billion yuan, a year-on-year increase of 21.8%, and a net profit of 1.131 billion yuan, a year-on-year decrease of 14.6% [1] - Q3 revenue showed rapid growth at 4.197 billion yuan, a year-on-year increase of 27.2% and a quarter-on-quarter increase of 27.5%, while net profit was 317 million yuan, a year-on-year decrease of 16.4% [1][2] - The adjusted net profit for Q3 was 444 million yuan, a year-on-year increase of 4.0%, with an adjusted net profit margin of 10.6%, down 2.4 percentage points year-on-year due to a decline in gross margin from product mix changes [1] Business Performance - The vaping electronic business is recovering, with self-owned brands achieving steady growth due to successful product iterations and localized marketing [1] - The OEM business is experiencing rapid growth, aided by increased enforcement against illegal products in the U.S. and the introduction of new products in Europe following a temporary ban [1] HNB Product Development - The company launched the HNB product glo Hilo in Japan in September, receiving positive feedback, and plans to enter Poland and Italy soon [2] - The company is developing an HNB technology platform to promote multi-technology research and development, actively expanding new products and customers [2] Profit Forecast and Investment Rating - Smoore International is positioned as a global leader in vaping technology, benefiting from stricter regulations in Europe and the U.S. and the exclusive partnership with British American Tobacco for HNB products [2] - The company maintains its profit forecast, expecting net profits of 1.33 billion, 2.22 billion, and 2.89 billion yuan for 2025-2027, corresponding to PE ratios of 67, 40, and 31 times, respectively, and maintains a "Buy" rating [2]

Core Viewpoint - The company's performance in Q3 2025 aligns with expectations, showing a revenue increase but a decline in net profit due to stock incentive expenses and ongoing high R&D investments [1][2]. Financial Performance - Revenue for the first three quarters of 2025 reached 10.21 billion yuan, a year-on-year increase of 21.8% - Net profit attributable to shareholders was 810 million yuan, a year-on-year decrease of 23.8% - Adjusted net profit after stock incentive expenses was 1.18 billion yuan, a slight increase of 0.1% [1]. Development Trends - Glo Hilo is expanding steadily in Japan and Poland, with positive sales momentum in the European vaping market - The company expects to see growth in revenue from HNB products and compliant vaping products in Europe, despite regulatory challenges in the U.S. [1][2]. Short-term Profitability and R&D - Short-term profitability may be slightly pressured due to increased orders from small clients in Europe and initial sales of HNB heating devices - The company is increasing R&D investments in vaping medical and HNB new businesses, which may impact net profit in Q3 2025 [2]. Long-term Growth Prospects - The company anticipates accelerated global expansion of Glo Hilo by 2026, which is expected to drive revenue growth - The vaping medical segment is expected to commercialize, opening up long-term growth opportunities [2]. Profit Forecast and Valuation - The forecast for net profit attributable to shareholders in 2025 has been reduced by 20% to 1.05 billion yuan, while the 2026 forecast has been increased by 11% to 1.88 billion yuan - The current stock price corresponds to a 47 times P/E ratio for 2026, with a target price maintaining a 69 times P/E ratio, indicating a potential upside of 46% [2].

Core Viewpoint - The company reported a significant increase in revenue for Q1-Q3 2025, but net profit showed a decline, indicating mixed financial performance amidst growth in specific business segments [1][2]. Financial Performance - For Q1-Q3 2025, the company achieved revenue of 10.21 billion yuan, a year-on-year increase of 21.8%, while net profit was 809 million yuan, a year-on-year decrease of 23.8% [1]. - In Q3 2025, the company recorded revenue of 4.197 billion yuan, a quarter-on-quarter increase of 27.5% and a year-on-year increase of 27.2%. Net profit for the same period was 317 million yuan, a quarter-on-quarter increase of 5.7% but a year-on-year decrease of 16.4% [1]. Business Segments - The heated tobacco and electronic vaporization businesses both experienced growth in Q3 2025, contributing to the record quarterly revenue [1]. - The company supported strategic clients in launching new heated tobacco products globally, leading to a significant increase in product shipments [1]. - The company also enhanced its localized operations and marketing efforts, which helped expand its consumer base and market share [1]. Product Development - BAT announced the launch of the gloHilo product line in Japan, Italy, Poland, and Serbia, aiming to reach 50 million adult consumers of smoke-free products by 2030 [2]. - The gloHiloPlus is the first two-piece heated product from the glo brand, featuring advanced heating technology and a mobile app for personalized settings [2]. Regulatory Developments - TranspireBio, a subsidiary of the company, successfully submitted an ANDA for Breo Ellipta, which, if approved, would grant the company a 180-day market exclusivity in the U.S. [2]. - Breo Ellipta is projected to generate sales of 2.02 billion USD in the U.S. in 2024, highlighting the potential impact of this regulatory milestone on the company's market position [2]. Profit Forecast and Investment Outlook - The company is expected to see significant contributions from its HNB business starting in 2026, with adjusted net profit forecasts for 2025-2027 set at 1.392 billion, 2.023 billion, and 2.759 billion yuan respectively [3]. - The company maintains a "buy" rating based on its technological and market leadership advantages [3].

Core Viewpoint - Smoore International (06969) announced the grant of a total of 540,000 award shares to 10 eligible participants under the revised share award plan, pending acceptance by the grantees [1] Group 1 - The company is set to issue 540,000 award shares [1] - The grant involves 10 eligible participants [1] - The issuance is contingent upon acceptance by the grantees [1]

Group 1 - The core point of the article is that Smoore International (06969) announced the grant of a total of 540,000 share awards to 10 eligible participants under the revised share award plan, pending acceptance by the grantees [1]

Group 1 - The core point of the article is that Smoore International (06969.HK) announced the grant of a total of 1.18 million stock options to 9 eligible participants as part of its revised stock option plan approved by shareholders on February 18, 2025 [1] Group 2 - The stock options will be granted on October 15, 2025, indicating a future commitment to incentivize key personnel within the company [1]

Core Viewpoint - Smoore International (06969.HK) announced the grant of a total of 540,000 award shares to 10 eligible participants under the revised share award plan, pending acceptance by the participants [1] Group 1 - The company will issue the shares on October 15, 2025 [1] - The grant is subject to acceptance by the participants [1]

Group 1 - The company, Smoore International (06969), announced the grant of a total of 1.18 million stock options to 9 eligible participants on October 15, 2025 [1] - The exercise price for the stock options is set at HKD 15.72 per share [1]

Group 1 - The company Smoore International (06969) announced the grant of a total of 1.18 million stock options to 9 eligible participants on October 15, 2025 [1] - The exercise price for the stock options is set at HKD 15.72 per share [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致之任何損 失承擔任何責任。 Smoore International Holdings Limited 思 摩 爾 國 際 控 股 有 限 公 司 （ 於開曼群島註冊成立的有限公司） （股份代號：6969） 授出獎勵股份 本公告乃根據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）第17.06A， 17.06B及17.06C條作出。茲提述思摩爾國際控股有限公司（「本公司」）日期為2025年2月18日 之 公 告（「 該 公 告 」）， 內 容 有 關 本 公 司 股 東 批 准 經 修 訂 股 份 獎 勵 計 劃（「 經 修 訂 股 份 獎 勵 計 劃」）。除文義另有所指外，本公告所用詞彙與該公告所界定者具有相同涵義。 授出獎勵股份 董事會宣佈，於2025年10月15日，本公司根據經修訂股份獎勵計劃之條款，向10名合資格 參與者（「承授人」），授出合共540,000股獎勵股份（「授出事項」），惟授出事項須待承授人接 ...